Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
SOUTHWALL TECHNOLOGIES INC (SWTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/01/2021 GN SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen's BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
03/22/2021 GN SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer
02/25/2021 GN SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
02/22/2021 GN SpringWorks Therapeutics to Present at Upcoming Investor Conferences
02/04/2021 GN SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day
01/05/2021 GN SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/15/2020 GN SpringWorks Therapeutics Announces Executive Leadership Promotions
11/24/2020 GN SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference
11/12/2020 GN SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
10/13/2020 GN SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
10/07/2020 GN SpringWorks Therapeutics Announces Pricing of Public Offering of Common Stock
10/06/2020 GN SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
10/05/2020 GN SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF-06863135 in Patients with Relapsed or Refractory Multiple Myeloma
09/22/2020 GN SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference
09/21/2020 GN Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
09/18/2020 GN SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
09/14/2020 GN SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
08/12/2020 GN SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
08/04/2020 GN SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
07/22/2020 GN SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors
06/22/2020 GN SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline's Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma
06/02/2020 GN SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
05/26/2020 GN SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors
05/12/2020 GN SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights
03/18/2020 GN SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039
03/12/2020 GN SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
02/18/2020 GN SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
01/13/2020 GN Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
01/06/2020 GN SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/09/2019 GN Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics' Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline's BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting
10/24/2019 GN SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)
09/24/2019 GN European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma
09/17/2019 GN SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter's Option to Purchase Additional Shares
09/12/2019 GN SpringWorks Therapeutics Announces Pricing Of Initial Public Offering
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy